Tarlatamab: a potential new option for recurrent small cell lung cancer.
作者信息
Addeo Alfredo, Banna Giuseppe Luigi, Friedlaender Alex
机构信息
Department of Oncology, University Hospital Geneva, Geneva, Switzerland.
Department of Oncology, Portsmouth Hospitals University NHS Trust, Cosham, Portsmouth, UK.
出版信息
Transl Lung Cancer Res. 2023 Jul 31;12(7):1628-1630. doi: 10.21037/tlcr-23-215. Epub 2023 Jun 5.
Abstract
摘要
相似文献
1
Tarlatamab: a potential new option for recurrent small cell lung cancer.塔勒妥单抗：复发性小细胞肺癌的一种潜在新选择。
Transl Lung Cancer Res. 2023 Jul 31;12(7):1628-1630. doi: 10.21037/tlcr-23-215. Epub 2023 Jun 5.
2
Tarlatamab-dlle: A New Hope for Patients with Extensive-Stage Small-Cell Lung Cancer.特泊替尼：广泛期小细胞肺癌患者的新希望。
Curr Treat Options Oncol. 2024 Nov;25(11):1337-1344. doi: 10.1007/s11864-024-01268-3. Epub 2024 Oct 11.
3
Tarlatamab: First Approval.特拉拉他单抗：首次批准。
Drugs. 2024 Aug;84(8):995-1003. doi: 10.1007/s40265-024-02070-z. Epub 2024 Jul 18.
4
Tarlatamab: the promising immunotherapy on its way from the lab to the clinic.塔勒妥单抗：从实验室走向临床的有前景的免疫疗法。
Transl Lung Cancer Res. 2023 Jun 30;12(6):1355-1357. doi: 10.21037/tlcr-23-115. Epub 2023 Mar 20.
5
Tarlatamab for Large Cell Neuroendocrine Carcinoma in a Young Adult: A Case Report.替雷他明治疗青年大细胞神经内分泌癌：一例报告
JTO Clin Res Rep. 2024 Jul 31;5(10):100712. doi: 10.1016/j.jtocrr.2024.100712. eCollection 2024 Oct.
6
DLL3: an emerging target in small cell lung cancer.DLL3：小细胞肺癌的一个新兴靶点。
J Hematol Oncol. 2019 Jun 18;12(1):61. doi: 10.1186/s13045-019-0745-2.
7
Human endoglin-CD3 bispecific T cell engager antibody induces anti-tumor effect .人内皮糖蛋白-CD3双特异性T细胞衔接抗体诱导抗肿瘤效应。
Theranostics. 2021 Apr 19;11(13):6393-6406. doi: 10.7150/thno.53121. eCollection 2021.
8
Targeting gastrin-releasing peptide receptors on small cell lung cancer cells with a bispecific molecule that activates polyclonal T lymphocytes.用一种激活多克隆T淋巴细胞的双特异性分子靶向小细胞肺癌细胞上的胃泌素释放肽受体。
Clin Cancer Res. 2006 Apr 1;12(7 Pt 1):2224-31. doi: 10.1158/1078-0432.CCR-05-1524.
9
The BiTE (bispecific T-cell engager) platform: Development and future potential of a targeted immuno-oncology therapy across tumor types.双特异性 T 细胞衔接器（BiTE）平台：一种针对多种肿瘤类型的靶向免疫肿瘤学治疗的开发和未来潜力。
Cancer. 2020 Jul 15;126(14):3192-3201. doi: 10.1002/cncr.32909. Epub 2020 May 13.
10
Treatment of hepatocellular carcinoma with a GPC3-targeted bispecific T cell engager.用靶向GPC3的双特异性T细胞衔接器治疗肝细胞癌。
Oncotarget. 2017 May 16;8(32):52866-52876. doi: 10.18632/oncotarget.17905. eCollection 2017 Aug 8.
引用本文的文献
1
Tarlatamab and the Future of Immunotherapy: A New Approach to Small Cell Lung Cancer.塔勒妥单抗与免疫疗法的未来：小细胞肺癌的新方法
Curr Ther Res Clin Exp. 2024 Dec 21;102:100773. doi: 10.1016/j.curtheres.2024.100773. eCollection 2025.
2
Tarlatamab-dlle: A New Hope for Patients with Extensive-Stage Small-Cell Lung Cancer.特泊替尼：广泛期小细胞肺癌患者的新希望。
Curr Treat Options Oncol. 2024 Nov;25(11):1337-1344. doi: 10.1007/s11864-024-01268-3. Epub 2024 Oct 11.
本文引用的文献
1
Tarlatamab, a First-in-Class DLL3-Targeted Bispecific T-Cell Engager, in Recurrent Small-Cell Lung Cancer: An Open-Label, Phase I Study.塔拉拉单抗，一种首创的 DLL3 靶向双特异性 T 细胞衔接器，用于复发性小细胞肺癌：一项开放标签、I 期研究。
J Clin Oncol. 2023 Jun 1;41(16):2893-2903. doi: 10.1200/JCO.22.02823. Epub 2023 Jan 23.
2
Efficacy and Safety of Rovalpituzumab Tesirine Compared With Topotecan as Second-Line Therapy in DLL3-High SCLC: Results From the Phase 3 TAHOE Study.与拓扑替康相比，罗伐匹妥珠单抗替西瑞林作为DLL3高表达小细胞肺癌二线治疗的疗效和安全性：3期TAHOE研究结果
J Thorac Oncol. 2021 Sep;16(9):1547-1558. doi: 10.1016/j.jtho.2021.02.009. Epub 2021 Feb 16.
3
FDA Approval Summary: Lurbinectedin for the Treatment of Metastatic Small Cell Lung Cancer.FDA 批准概要：Lurbinectedin 治疗转移性小细胞肺癌。
Clin Cancer Res. 2021 May 1;27(9):2378-2382. doi: 10.1158/1078-0432.CCR-20-3901. Epub 2020 Dec 7.
4
Carboplatin plus etoposide versus topotecan as second-line treatment for patients with sensitive relapsed small-cell lung cancer: an open-label, multicentre, randomised, phase 3 trial.卡铂联合依托泊苷与拓扑替康二线治疗敏感复发性小细胞肺癌的疗效比较：一项开放标签、多中心、随机、III 期临床试验。
Lancet Oncol. 2020 Sep;21(9):1224-1233. doi: 10.1016/S1470-2045(20)30461-7.
5
The Role of Performance Status in Small-Cell Lung Cancer in the Era of Immune Checkpoint Inhibitors.在免疫检查点抑制剂时代小细胞肺癌中体能状态的作用。
Clin Lung Cancer. 2020 Nov;21(6):e539-e543. doi: 10.1016/j.cllc.2020.04.006. Epub 2020 Apr 30.
6
Outcomes with immune checkpoint inhibitors for relapsed small-cell lung cancer in a Swiss cohort.瑞士队列中小细胞肺癌复发患者使用免疫检查点抑制剂的结果。
Cancer Immunol Immunother. 2020 Aug;69(8):1605-1613. doi: 10.1007/s00262-020-02565-0. Epub 2020 Apr 19.
7
Rovalpituzumab tesirine, a DLL3-targeted antibody-drug conjugate, in recurrent small-cell lung cancer: a first-in-human, first-in-class, open-label, phase 1 study.洛伐匹妥珠单抗替西瑞林，一种靶向DLL3的抗体药物偶联物，用于复发性小细胞肺癌：一项首次人体、同类首创、开放标签的1期研究。
Lancet Oncol. 2017 Jan;18(1):42-51. doi: 10.1016/S1470-2045(16)30565-4. Epub 2016 Dec 5.
8
A DLL3-targeted antibody-drug conjugate eradicates high-grade pulmonary neuroendocrine tumor-initiating cells in vivo.一种靶向DLL3的抗体药物偶联物可在体内根除高级别肺神经内分泌肿瘤起始细胞。
Sci Transl Med. 2015 Aug 26;7(302):302ra136. doi: 10.1126/scitranslmed.aac9459.
9
Comprehensive genomic profiles of small cell lung cancer.全面基因组分析小细胞肺癌
Nature. 2015 Aug 6;524(7563):47-53. doi: 10.1038/nature14664. Epub 2015 Jul 13.
10
Phase II study of bendamustine in relapsed chemotherapy sensitive or resistant small-cell lung cancer.苯达莫司汀用于复发的化疗敏感或耐药小细胞肺癌的II期研究。
J Thorac Oncol. 2014 Apr;9(4):559-62. doi: 10.1097/JTO.0000000000000079.
Zotero 插件